Investigational tetra-specific (multispecific) antibody biologic given by weekly IV infusion for relapsed/refractory B-cell malignancies (CLL/SLL and other NHL); designed to bind multiple antigens to enhance immune-mediated killing and reduce antigen escape.
Tetra-specific T‑cell–engaging antibody that binds ROR1 on tumor cells and CD3 on T cells to redirect cytotoxic T lymphocytes, while simultaneously blocking PD-L1 to relieve PD-1–mediated inhibition and agonizing 4-1BB to provide costimulation. The combined actions enhance T-cell activation and CTL-mediated lysis of ROR1+ malignant B cells and help mitigate antigen escape.
NO
INDIRECT
The PD-L1 arm functions as checkpoint blockade to relieve PD-1–mediated inhibition; T cells are redirected via CD3 to kill ROR1+ cells. PD-L1 expression alone does not trigger cytotoxic engagement.
Investigational tetra-specific (multispecific) antibody biologic given by weekly IV infusion for relapsed/refractory B-cell malignancies (CLL/SLL and other NHL); designed to bind multiple antigens to enhance immune-mediated killing and reduce antigen escape.
Tetra-specific T‑cell–engaging antibody that binds ROR1 on tumor cells and CD3 on T cells to redirect cytotoxic T lymphocytes, while simultaneously blocking PD-L1 to relieve PD-1–mediated inhibition and agonizing 4-1BB to provide costimulation. The combined actions enhance T-cell activation and CTL-mediated lysis of ROR1+ malignant B cells and help mitigate antigen escape.
NO
INDIRECT
The 4-1BB (CD137) arm acts as a costimulatory agonist on T cells, enhancing their activation. GNC-035 redirects CD3+ T cells to kill ROR1+ tumor cells (with PD-L1 blockade relieving inhibition); 4-1BB–expressing cells themselves are not targeted for lysis.
TROP-2–directed antibody–drug conjugate that delivers SN-38 (topoisomerase I inhibitor) to TROP-2–expressing tumor cells.
TROP-2–directed antibody–drug conjugate in which a humanized anti–TROP-2 monoclonal antibody (hRS7) delivers SN-38 (topoisomerase I inhibitor) to TROP-2–expressing tumor cells. Binding triggers internalization and linker cleavage to release SN-38, which stabilizes topoisomerase I–DNA complexes, causing DNA breaks, blocking replication, and inducing apoptosis.
YES
DIRECT
The ADC binds TROP-2, is internalized, and releases SN-38 (topoisomerase I inhibitor) inside the cell, causing DNA damage and apoptosis.
TROP-2–directed antibody–drug conjugate that delivers SN-38 (topoisomerase I inhibitor) to TROP-2–expressing tumor cells.
TROP-2–directed antibody–drug conjugate in which a humanized anti–TROP-2 monoclonal antibody (hRS7) delivers SN-38 (topoisomerase I inhibitor) to TROP-2–expressing tumor cells. Binding triggers internalization and linker cleavage to release SN-38, which stabilizes topoisomerase I–DNA complexes, causing DNA breaks, blocking replication, and inducing apoptosis.
NO
INDIRECT
The ADC binds TROP-2 on tumor cells, is internalized, and releases SN-38, which inhibits topoisomerase I to cause DNA damage and apoptosis. Topoisomerase I expression alone does not direct drug binding or cell killing.